Details of issuance or disposal
Monthly exercise status of the Eighth Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment terms)
Shares delivered during the month: 60,000 shares (60,000 new shares and 0 treasury shares transferred)
The lower thin line represents the existing number of shares to which these shares will be added.
0.6% (exercise ratio subject to the exercise limit: 60,000 shares delivered during the month / 9,252,901 listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of the Eighth Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment terms) |
| Number of shares to be issued or disposed of | Shares delivered during the month: 60,000 shares (60,000 new shares and 0 treasury shares transferred) |
| Intended allottee | EVO FUND (the allottee at the time of issuance on 12 December 2025) |
| Dilution Rate | 0.6% (exercise ratio subject to the exercise limit: 60,000 shares delivered during the month / 9,252,901 listed shares as of the payment date for the issuance) |
| Total number of issued shares | As of the end of the preceding month: 13,332,901 issued shares → Not disclosed |
| Exercise price | Exercise price during the month: ¥493–¥527. The exercise price is subject to an adjustment provision, but the adjustment floor is Not disclosed. |
| Number of Stock Acquisition Rights | Total issued: 85,000 rights; exercised during the month: 600 rights; unexercised at the end of the preceding month: 44,200 rights; unexercised at month-end: 43,600 rights |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | 12 December 2025: Issuance of 85,000 Series 8 Stock Acquisition Rights with an exercise price adjustment provision, allocated to EVO FUND. Amount: Not disclosed |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status in September 2026 of the Series 8 Stock Acquisition Rights issued on 12 December 2025.